Pomona Ricerca

Pomona Ricerca is an Italian biotech firm with a dual-focused business model combining proprietary R&D and fee-for-service commercial activities. Its core R&D strategy involves cloning and characterizing human broadly neutralizing antibodies against viruses like HCV, HIV, Influenza A, and JC virus, with the aim of out-licensing therapeutic candidates at the pre-clinical stage or developing epitope-based vaccines. The company also generates revenue by marketing high-quality antibodies and proteins and offering custom antibody/protein services to other biotech and pharmaceutical entities. With a strong IP portfolio and international collaborations, Pomona positions itself as a partner for advancing novel infectious disease therapeutics.

Platform for cloning, characterizing, and engineering human broadly neutralizing monoclonal antibodies (bNAbs) against viral pathogens. Utilizes antibody discovery for both therapeutic development and rational vaccine design via an anti-idiotype response strategy.

Pomona operates in a highly competitive space for infectious disease antibodies and vaccines, competing with large pharma and well-funded biotechs. Its niche differentiation lies in its anti-idiotype vaccine platform and its hybrid service-based model, which may provide stability but also pits it against established reagent suppliers and CROs.